Because these genes are thought to drive tumorigenesis, the genetic status and expression level of MYC and MCL1 for each line is indicated (25); however, the correlations between these aberrations and enitociclib sensitivity and resistance were not possible as most lymphoma cell lines are sensitive to enitociclib treatment (Supplementary Table S1). The gene discussed is MYC; the disease is lymphoma.